目的 探討心元膠囊聯(lián)合福辛普利鈉片治療原發(fā)性高血壓的臨床療效。方法 選取2013年12月-2016年1月在河北大學(xué)附屬醫(yī)院接受治療的初發(fā)原發(fā)性高血壓患者86例，按照數(shù)表法將患者隨機(jī)分為對(duì)照組和治療組，每組各43例。對(duì)照組晨起口服福辛普利鈉片，10 mg/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服心元膠囊，3粒/次，3次/d。兩組患者均治療8周。觀察兩組的臨床療效，比較兩組的血脂、血壓情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為81.39%、93.02%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組總膽固醇、甘油三酯和低密度脂蛋白水平均下降，而高密度脂蛋水平均上升，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組收縮壓和舒張壓均顯著下降，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的下降程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 心元膠囊聯(lián)合福辛普利鈉片具有較好的臨床療效，調(diào)節(jié)血脂水平，可有效降低患者血壓，安全性好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Xinyuan Capsules combined with Fosinopril Sodium Tablets in treatment of primary hypertension. Methods Patients (86 cases) with primary hypertension in Affiliated Hospital of Hebei University from December 2013 to January 2016 were randomly divided into control and treatment groups, and each group had 43 cases. Patients in the control group were po administered with Fosinopril Sodium Tablets in the morning, 10 mg/time, once daily. Patients in the treatment group were po administered with Xinyuan Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and blood lipid and blood pressure in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.39% and 93.02%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of total cholesterol, triglyceride, and low density lipoprotein in two groups were decreased, but the levels of high density lipoprotein were increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, systolic and diastolic blood pressures in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xinyuan Capsules combined with Fosinopril Sodium Tablets has clinical curative effect in treatment of primary hypertension, can regulate blood lipid level, and significantly decrease blood pressure with good safety, which has a certain clinical application value.